Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis

Completed · Phase 2

Conditions studied: Psoriasis Vulgaris

In brief

An international, multi-centre, prospective, open-label, non-controlled, single-group, 4-week trial in adolescent subjects with plaque psoriasis.

Key facts

Study ID

NCT02387853

Run by

LEO Pharma

People needed

117

Starts

2016-03-01

Expected to finish

2018-03-28

Last updated by the study team

2025-03-10

Who can join

Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Lucile Packard Children's Hospital at Stanford — Palo Alto, California, United States
• Redwood Family Dermatology — Santa Rosa, California, United States
• Hamzavi Dermatology — Fort Gratiot, Michigan, United States
• Greenwich Village Dermatology — New York, New York, United States
• Skin Speciality Dermatology — New York, New York, United States
• Dermatology Treatment and Research Center PA — Dallas, Texas, United States
• UMC St Radboud — Nijmegen, Netherlands
• MULTIKLINIKA SALUTE Sp zo.o. — Katowice, Poland
• Spitalul Clinic de Boli Infectioase si Tropicale — Bucharest, Romania

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.